Jenny Powers

Researchers suggest that monitoring for the loss of CD62L expression on CD4+ T cells is a biomarker for risk assessment in patients treated with natalizumab who may develop PML, since other treatments do not show this pattern of C62L loss of expression.

Late-breaking study results reported at ECTRIMS 2013 indicate that neurofilament levels may be reliable biomarkers of nerve damage and disease progression in patients with relapsing multiple sclerosis.

Study results show that treatment with riluzole did not slow the rate of brain atrophy and did not demonstrate a detectable neuroprotective effect in patients with early RRMS.

Patients treated with oromucosal nabiximols spray experienced up to 30% reduction in spasticity, as measured by a numerical rating scale, after 12 months of treatment.

Nonadherence is highest in patients undergoing treatment with subcutaneous or intramuscular injection formulations of DMT.

Clinicians can use the MSPT, an iPad-based neurological performance test that simulates and extends the Multiple Sclerosis Functional Composite, to measure motor and visual function in patients with multiple sclerosis.

Patients with relapsing-remitting multiple sclerosis treated for two years with alemtuzumab demonstrated improved disease-related disability scores compared to patients who received treatment with subcutaneous interferon beta-1a.

Study results show that hip flexion weakness and, to a lesser extent, ankle dorsiflexion weakness have the greatest impact upon changes in walking speed as MS progresses

Data indicate patients with relapsing remitting multiple sclerosis (RRMS) treated with BG-12 (dimethyl fumarate) showed no clinical disease activity for up to two years.